INDICATIONS AND USAGE

AVEED® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

- Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
- Hypogonadotropic hypogonadism (congenital or acquired): idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone concentrations but have gonadotropins in the normal or low range.

AVEED® should only be used in patients who require testosterone replacement therapy and in whom the benefits of the product outweigh the serious risks of pulmonary oil microembolism and anaphylaxis.

Limitations of use:

- Safety and efficacy of AVEED® in males less than 18 years old have not been established.

CONTRAINDICATIONS

- Men with carcinoma of the breast or known or suspected carcinoma of the prostate.
- Women who are or may become pregnant, or who are breastfeeding. Testosterone can cause fetal harm when administered to a pregnant woman. AVEED® may cause serious adverse reactions in nursing infants. Exposure of a fetus or nursing infant to androgens may result in varying degrees of virilization.
- Men with known hypersensitivity to AVEED® or any of its ingredients (testosterone undecanoate, refined castor oil, benzyl benzoate).

WARNINGS AND PRECAUTIONS

- Serious Pulmonary Oil Microembolism (POME) Reactions and Anaphylaxis

Serious POME reactions, involving cough, urge to cough, dyspnea, hyperhidrosis, throat tightening, chest pain, dizziness, and syncope, have been reported to occur during or immediately after the injection of intramuscular testosterone undecanoate 1000 mg (4 mL). The majority of these events lasted a few minutes and resolved with supportive measures; however, some lasted up to several hours and some required emergency care and/or hospitalization. To minimize the risk of intravascular injection of AVEED®, care should be taken to inject the preparation deeply into the gluteal muscle, being sure to follow the recommended procedure for intramuscular administration.

In addition to serious POME reactions, episodes of anaphylaxis, including life-threatening reactions, have also been reported to occur following the injection of intramuscular testosterone undecanoate. Both serious POME reactions and anaphylaxis can occur after any injection of testosterone undecanoate during the course of therapy, including after the first dose. Patients with suspected hypersensitivity reactions to AVEED® should not be re-treated with AVEED®.

Following each injection of AVEED®, observe patients in the healthcare setting for 30 minutes in order to provide appropriate medical treatment in the event of serious POME reactions or anaphylaxis.

- AVEED® Risk Evaluation and Mitigation Strategy (REMS) Program

AVEED® is available only through a restricted program called the AVEED® REMS Program because of the risk of serious POME and anaphylaxis.

In order to be in compliance with the PhRMA Code on Interactions with Healthcare Professionals and other regulations and policies, attendance to this event is limited to healthcare professionals (HCPs) only. Accordingly, attendance by guests or spouses is not permitted.

This event will include the provision of modest food and beverages. Endo Pharmaceuticals Inc. does not intend to offer such provisions to HCPs whose institutions prohibit such offerings, nor does Endo offer food or beverages where federal or state laws (e.g., Minnesota and Vermont) limit an HCP’s ability to accept food or beverages. Accordingly, please consult your legal or ethics advisor regarding any applicable limitation before attending this event. By attending this event, you represent that it is permissible for you to accept food and beverages under these laws or policies.

Please note that Endo is required to report the value of food and beverages provided pursuant to applicable federal and/or state laws.
IMPORTANT SAFETY INFORMATION for AVEED® (CONT)

Notable requirements of the AVEED® REMS Program include the following:

- Healthcare providers who prescribe AVEED® must be certified with the REMS Program before ordering or dispensing AVEED®.
- Healthcare settings must be certified with the REMS Program and have healthcare providers who are certified before ordering or dispensing AVEED®. Healthcare settings must have on-site access to equipment and personnel trained to manage serious POME and anaphylaxis.
- Further information is available at www.AveedREMS.com or call 1-855-755-0494.
- Or call 1-855-755-0494.
- Further information is available at www.AveedREMS.com

ADVERSE REACTIONS

AVEED® was evaluated in an 84-week clinical study using a dose regimen of 750 mg (3 mL) at initiation, at 4 weeks, and every 10 weeks thereafter in 153 hypogonadal men. The most commonly reported adverse reactions (≥2%) were: acne, injection site pain, prostate specific antigen increased, hypogonadism, estradiol increased, fatigue, irritability, hemoglobin increased, insomnia, and mood swings.

In the 84-week clinical trial, 7 patients (4.6%) discontinued treatment because of adverse reactions. Adverse reactions leading to discontinuation included: hematoctrit increased, estradiol increased, prostatic specific antigen increased, prostate cancer, mood swings, prostatic dysplasia, acne, and deep vein thrombosis.

- **Postmarketing Experience**
  - **Pulmonary Oil Microembolism (POME) and Anaphylaxis**
    - Serious pulmonary oil microembolism (POME) reactions, involving cough, urge to cough, dyspnea, hyperhidrosis, throat tightening, chest pain, dizziness, and syncope, have been reported to occur during or immediately after the injection of intramuscular testosterone undecanoate 1000 mg (4 mL) in post-approval use outside the United States.
    - In addition to serious POME reactions, episodes of anaphylaxis, including life-threatening reactions, have also been reported to occur following the injection of intramuscular testosterone undecanoate in post-approval use outside of the United States.

- **DRUG INTERACTIONS**
  - **Oral Anticoagulants** - Due to lack of controlled evaluations in women and potential virilizing effects, AVEED® is not indicated for use in women.
  - **Potential for Adverse Effects on Spermatogenesis** - With large doses of exogenous androgens, including AVEED®, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH) which could possibly lead to adverse effects on semen parameters including sperm count.
  - **Hepatic Adverse Effects** - Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliopsis hepatitis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliopsis hepatitis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate, which elevates blood levels for prolonged periods, has produced multiple hepatic adenomas. AVEED® is not known to produce these adverse effects. Nonetheless, patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). If these occur, promptly discontinue AVEED® while the cause is evaluated.
  - **Edema** - Androgens, including AVEED®, may promote retention of sodium and water. Edema with or without congestive heart failure may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.
  - **Gynecomastia** - Gynecomastia occasionally develops and occasionally persists in patients being treated for hypogonadism.
  - **Sleep Apnea** - The treatment of hypogonadal men with testosterone products may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung diseases.
  - **Lipids** - Changes in serum lipid profile may require dose adjustment of lipid lowering drugs or discontinuation of testosterone therapy.
  - **Hypercalcemia** - Androgens, including AVEED®, should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria). Regular monitoring of serum calcium concentrations is recommended in these patients.
  - **Decreased Thyroxine-binding Globulin** - Androgens, including AVEED®, may decrease concentrations of thyroxine-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.
  - **Laboratory Monitoring** - Monitor prostatic specific antigen (PSA), hemoglobin, hematocrit, and lipid concentrations at the start of treatment and periodically thereafter.

**USE IN SPECIFIC POPULATIONS**

- **Geriatric Use** - There have not been sufficient numbers of geriatric patients in controlled clinical studies with AVEED® to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. There are insufficient long-term safety data in geriatric patients to assess the potential risks of cardiovascular disease and prostate cancer.

**DRUG ABUSE**

AVEED® contains testosterone undecanoate, a Schedule III controlled substance in the Controlled Substances Act. Anabolic steroids, such as testosterone, are abused. Abuse is often associated with adverse physical and psychological effects.

**Click here to see the full Prescribing Information including Boxed Warning or go to AveedUSA.com.**